C6orf115
- Known as:
- C6orf115
- Catalog number:
- 003177A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- C6orf115
Related genes to: C6orf115
- Gene:
- ABRACL NIH gene
- Name:
- ABRA C-terminal like
- Previous symbol:
- C6orf115
- Synonyms:
- PRO2013, HSPC280, Costars
- Chromosome:
- 6q24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2003-05-29
- Date modifiied:
- 2014-11-19
Related products to: C6orf115
Related articles to: C6orf115
- Bladder cancer (BLCA) is a malignant tumor originating from the urothelial lining, characterized by a complex tumor microenvironment (TME) and heterogeneous tumor mutation burden (TMB). Cancer-associated epithelial cells (EpiCs) exhibit substantial heterogeneity during BLCA initiation and progression. Therefore, elucidating the diversity and functional states of EpiCs is essential for improving future diagnostic and therapeutic strategies. - Source: PubMed
Publication date: 2026/01/26
Li LinLi QianyueLiu JiaxinWang YifanMa YanjunTang LeiZhao Yawei - Previous studies have suggested a potential role for paraptosis-related genes (PRGs) in cancer pathogenesis, yet their prognostic significance and therapeutic efficacy in gastric cancer (GC) remain largely unexplored. This study aims to investigate the function of PRGs in GC and offer valuable insights for clinical assessment of patient prognosis. Single-cell RNA sequencing (scRNA-seq) and the cancer genome atlas (TCGA)-GC transcriptomic data were acquired from public databases, with PRGs derived from Literature. Differential expressed genes 1 (DEGs1) were identified through scRNA-seq differential analysis. Prognostic genes were determined via regression analysis, followed by construction of prognostic models and nomograms to validate risk scores as independent predictors. Immune infiltration analysis assessed prognostic genes' impact on the tumor microenvironment. Cell trajectory analysis elucidated critical differentiation patterns between GC and normal groups, while cell communication analysis revealed interactions between key cellular subpopulations. In this study, 3,177 DEGs were identified from scRNA-seq. A risk model using 8 prognostic genes predicted GC patient survival outcomes effectively. These genes were also validated as independent prognostic factors in a nomogram. High-risk patients showed significantly increased immunotherapy resistance. T cells and fibroblasts were more differentiated in GC patients, while neutrophils had the highest interaction intensity in both GC and normal groups, with the CXCL8-CXCR2 interaction being most significant (p < 0.01). This study identified 8 prognostic genes (ABRACL, RANBP1, RAMP1, CCT2, AKR1A1, NPTN, ITGA8, CLU) and combined single-cell and transcriptome analysis to offer new insights into potential GC treatment strategies. - Source: PubMed
Publication date: 2025/10/15
Liu ZhengliangGao YingZhang WenjieLi LinchuanDing HuanxinZhang ShuangchangFu XushuoZhang DexuCai YunluZhu JiankangZhang YunZhang Guangyong - This study aims to elucidate the functional mechanisms of LncRNA DRAIC in renal cell carcinoma, particularly its regulation of tumor progression via microRNA-145-3p and ABRACL. The downstream targets of LncRNA DRAIC were predicted using databases, and their interactions with microRNA-145-3p were experimentally validated. The effects of LncRNA DRAIC overexpression on the proliferation, invasion, and migration of renal carcinoma cells were evaluated using stable cell lines, CCK-8 assays, Transwell assays, subcutaneous tumor transplantation in nude mice, and in vivo fluorescence imaging experiments. Techniques such as Western blot and RT-PCR were utilized to monitor the expression levels of ABRACL under the regulation of LncRNA DRAIC, further confirming its role in renal carcinoma cell functions. Overexpression of LncRNA DRAIC significantly enhanced the proliferation, invasion, and migration capabilities of renal carcinoma cells. Moreover, it was discovered that LncRNA DRAIC regulates the expression of ABRACL by modulating microRNA-145-3p, thereby affecting the functionality of renal carcinoma cells. This reveals the critical mechanisms of LncRNA DRAIC in renal cell carcinoma, where it governs tumor cell biology through microRNA-145-3p and ABRACL, offering new targets and theoretical foundations for the treatment of renal cell carcinoma. - Source: PubMed
Publication date: 2025/07/10
Wei ShufeiSu JianzhiPan ZhenhuiLiu RuiZhang XiaoyuMa YongliangQi Pan - Ovarian cancer (OC) stands as the leading cause of cancer-related deaths among women, globally, owing to metastasis and acquired chemoresistance. Cancer stem cells (CSCs) are accountable for tumor initiation and exhibit resistance to chemotherapy and radiotherapy. Identifying stemness-related biomarkers that can aid in the stratification of risk and the response to chemotherapy for OC is feasible and critical. Gene expression and clinical data of patients with OC were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database. Four thousand three hundred seventeen stemness-related genes (SRGs) were acquired from the StemChecker database. TCGA was used as the training dataset, while GSE30161 served as validation dataset. Univariate Cox regression analysis was used to identify overall survival (OS)-related SRGs, and multivariate Cox regression analysis and random survival forest analysis were used for generating stemness-relevant prognostic model. Kaplan-Meier plots were used to visualize survival functions. Receiver operating characteristic (ROC) curves were used to assess the prognostic predictive ability of SRG-based features. Associations between signature score, tumor immune phenotype, and response to chemotherapy were analyzed via TIMER 2.0 and oncoPredict R package, respectively. A cohort of Shanghai Cancer Center was employed to verify the predictive robustness of the signature with respect to chemotherapy response. Seven SRGs (actin-binding Rho activating C-terminal like (ABRACL), growth factor receptor bound protein 7 (GRB7), Lin-28 homolog B (LIN28B), lipolysis stimulated lipoprotein receptor (LSR), neuromedin U (NMU), Solute Carrier Family 4 Member 11 (SLC4A11), and thymocyte selection associated family member 2 (THEMIS2)) were found to have excellent predictive potential for patient survival. Patients in the high stemness risk group presented a poorer prognosis ( < 0.0001), and patients with lower stemness scores were more likely to benefit from chemotherapy. Several tumorigenesis pathways, such as mitotic spindle and glycolysis, were enriched in the high stemness risk group. Tumor with high-risk scores tended to be in a status of relatively high tumor infiltration of CD4+ T cells, neutrophils, and macrophages, while tumor with low-risk scores tended to be in a status of relatively high tumor infiltration of CD8+ T cells. The stemness-relevant prognostic gene signature has the potential to serve as a clinically helpful biomarker for guiding the management of OC patients. - Source: PubMed
Publication date: 2025/03/27
Zhou KaixiaMa XiaoluYan TianqingZheng HuiXie SuhongGuo LinLu Renquan - Gastric cancer (GC) is a predominant health concern in many countries. Actin-binding Rho activating C-terminal-like (ABRACL) belongs to a new family of low molecular weight proteins and has been implicated in cancers. This study was implemented to elucidate the role and mechanism of ABRACL in GC. - Source: PubMed
Publication date: 2024/09/11
Guo KaiGao Xiao